87
Participants
Start Date
May 31, 2016
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Pembrolizumab
IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
Carboplatin
IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
Gemcitabine
IV infusion of 800 mg/m\^2 given on days one and eight of each 21 day treatment cycle.
Montefiore Medical Center, The Bronx
Indiana University, Indianapolis
Washington University in St. Louis, St Louis
Duke University, Durham
University of Wisconsin, Madison
Fox Chase Cancer Center - Philadelphia, Philadelphia
University of Wisconsin, Madison
OTHER
Fox Chase Cancer Center
OTHER